文献速递治疗药物监测与药物基因组学特殊人群用药

系统性红斑狼疮患者泼尼松龙群体药代动力学建模:暴露量与疾病活动度分析

Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity.
PubMed 文献 · Br J Clin Pharmacol · 2025-05-23

本研究纳入66例活动性SLE成人与儿童患者,前瞻性随访获得242个观察值,采用液相色谱-质谱法测定泼尼松龙浓度并用Monolix建立一室开放模型。模型预测游离泼尼松龙清除率和分布容积按体重异速缩放,典型估计值分别为54 L/h/70 kg和235 L/70 kg,生物利用度随剂量非线性下降。3个月应答者与未应答者的泼尼松龙累积暴露量无差异,目前尚缺乏明确的药代动力学靶标。

要点

  • 游离泼尼松龙清除率54 L/h/70 kg,分布容积235 L/70 kg
  • 生物利用度随剂量增加呈非线性下降
  • 3个月应答与未应答者累积暴露量无差异

核心结论

  • 泼尼松龙累积暴露量在3个月应答与未应答的SLE患者间无差异,尚缺乏明确的毒性或疗效药代动力学靶标。

研究设计与样本

  • 前瞻性研究纳入66例活动性SLE成人和儿童患者,共242个观察值,采用液相色谱-质谱法测定血浆泼尼松龙浓度,并用Monolix软件分析。
  • 药代动力学模型为一室开放模型,含吸收滞后时间,代表从无活性泼尼松转化为活性泼尼松龙的吸收与代谢延迟。

主要发现

  • 游离泼尼松龙清除率(CLu/F)和分布容积(Vu/F)按体重异速缩放,典型群体估计值(95%CI)分别为54(48-62)L/h/70 kg和235(203-274)L/70 kg。
  • 生物利用度参数随剂量呈非线性下降。
  • 3个月应答者与未应答者的泼尼松龙累积暴露量无差异。

临床怎么用

  • 当前证据尚不支持基于泼尼松龙暴露量常规开展治疗药物监测以指导SLE剂量调整。

局限性

  • 关于毒性或疗效的稳健药代动力学靶标尚未明确界定,有待进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Prednisone is a widely used glucocorticoid in the treatment of lupus, although its dosing is often determined empirically. Prednisolone, the active metabolite of prednisone, is found in its free form in the serum. The goal of this study was to develop a population pharmacokinetic model in patients with systemic lupus erythematosus (SLE) to forecast free prednisolone concentrations and its association with disease activity. METHODS: A total of 66 active SLE patients (adults and children) were included, and followed up prospectively (242 observations available). Plasma prednisolone concentrations were assessed using liquid chromatography-mass spectrometry, and the data were analysed using Monolix software. The pharmacokinetic model was a one-compartment open model with absorption lag time representing the delay for both absorption and metabolism from inactive (prednisone) to active form (prednisolone). This model predicted free concentrations, which were then used to calculate total concentrations based on established binding constants. RESULTS: Free prednisolone clearance (CLu/F) and volume of distribution (Vu/F) were scaled allometrically to body weight. The typical population estimates (95% confidence interval) were 54 (48-62) L/h/70 kg and 235 (203-274) L/70 kg, respectively. Additionally, the bioavailability parameter was found to decrease non-linearly with the dose. Prednisolone cumulative exposure was not different between patients who responded at 3 months and those who did not. CONCLUSIONS: Robust pharmacokinetic targets are not yet clearly defined regarding toxicity or efficacy and are warranted in order to make a valuable contribution to prednisolone therapeutic drug monitoring in the context of SLE.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Bouazza N, Semeraro M, Lui G, et al. Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity. Br J Clin Pharmacol. 2025. PMID: 40411119. doi:10.1002/bcp.70103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。